| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE45313 | SANOFI-AVENTIS US | Exendin variant peptides |
Jul, 2020
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9855388 | SANOFI-AVENTIS US | Dosing and drive mechanism for drug delivery device |
Apr, 2029
(4 years from now) | |
| US8915888 | SANOFI-AVENTIS US | Dosing and drive mechanism for drug delivery device |
Jun, 2030
(6 years from now) | |
| US9981013 | SANOFI-AVENTIS US | Use of AVE0010 for the treatment of diabetes mellitus type 2 |
Aug, 2030
(6 years from now) | |
| US10028910 | SANOFI-AVENTIS US | Pharmaceutical composition comprising a GLP-1-agonist and methionine |
Nov, 2030
(6 years from now) | |
| US9707176 | SANOFI-AVENTIS US | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
Nov, 2030
(6 years from now) | |
| US9308329 | SANOFI-AVENTIS US | Medication delivery device and method for operating a medication delivery device |
Dec, 2030
(6 years from now) | |
| US8475414 | SANOFI-AVENTIS US | Medication delivery device and method for operating a medication delivery device |
Dec, 2030
(6 years from now) | |
| US8882721 | SANOFI-AVENTIS US | Drive assembly suitable for use in a drug delivery device and drug delivery device |
Jun, 2031
(7 years from now) | |
| US9084853 | SANOFI-AVENTIS US | Drive mechanism for a drug delivery device and drug delivery device |
Oct, 2031
(7 years from now) | |
| US9511193 | SANOFI-AVENTIS US | Assembly and indicator for a drug delivery device |
Jan, 2032
(7 years from now) | |
| US9440029 | SANOFI-AVENTIS US | Drive mechanism for a drug delivery device and drug delivery device |
Jan, 2032
(7 years from now) | |
| US9072836 | SANOFI-AVENTIS US | Drive mechanism for a drug delivery device and drug delivery device |
Mar, 2032
(7 years from now) | |
| US9821032 | SANOFI-AVENTIS US | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
May, 2032
(8 years from now) | |
| US9408893 | SANOFI-AVENTIS US | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
Aug, 2032
(8 years from now) | |
| US10201663 | SANOFI-AVENTIS US | Assembly for a drug delivery device |
Mar, 2034
(9 years from now) | |
Adlyxin is owned by Sanofi-Aventis Us.
Adlyxin contains Lixisenatide.
Adlyxin has a total of 16 drug patents out of which 1 drug patent has expired.
Expired drug patents of Adlyxin are:
- USRE45313
Adlyxin was authorised for market use on 27 July, 2016.
Adlyxin is available in solution;subcutaneous dosage forms.
Adlyxin can be used as improvement in glycemic control in type 2 diabetes mellitus patients by use of a pen injector, combination treatment with a glitazone for improvement of glycemic control in type 2 diabetes mellitus patients, combination treatment with insulin glargine with or without metformin for improvement of glycemic control in type 2 diabetes mellitus patients, improvement of glycemic control in type 2 diabetes patients by administering a starting dose of 10 mcg for 14 days and increasing to a maintenance dose of 20 mcg on day 15.
Drug patent challenges can be filed against Adlyxin from 27 July, 2020.
The generics of Adlyxin are possible to be released after 10 March, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 27, 2021 |
Drugs and Companies using LIXISENATIDE ingredient
NCE-1 date: 27 July, 2020
Market Authorisation Date: 27 July, 2016
Treatment: Improvement in glycemic control in type 2 diabetes mellitus patients by use of a pen injector; Improvement of glycemic control in type 2 diabetes patients by administering a starting dose of 10 mcg fo...
Dosage: SOLUTION;SUBCUTANEOUS
ADLYXIN family patents
List of large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| USRE45313 | NA | Exendin variant peptides |
Jul, 2025
(1 year, 2 months from now) |
Ingredients: LIXISENATIDE